

### GAGE2B Antibody (N-term) Blocking Peptide Synthetic peptide

Catalog # BP13173a

### Specification

# GAGE2B Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

### <u>Q13066</u>

## GAGE2B Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 2574;645037

**Other Names** 

G antigen 2B/2C, GAGE-2B, GAGE-2C, Cancer/testis antigen 42, CT42, G antigen 2C, GAGE2B, GAGE2

### Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13173a was selected from the N-term region of GAGE2B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

### Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## GAGE2B Antibody (N-term) Blocking Peptide - Protein Information

Name GAGE2B

Synonyms GAGE2

**Function** Antigen, recognized on melanoma by autologous cytolytic T- lymphocytes.

**Tissue Location** Expressed in a variety of tumor tissues but not in normal tissues, except testis.

## GAGE2B Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

#### Blocking Peptides

### GAGE2B Antibody (N-term) Blocking Peptide - Images

### GAGE2B Antibody (N-term) Blocking Peptide - Background

This gene belongs to a family of genes that are expressed a variety of tumors but not in normal tissues, except for thetestis. The sequences of the family members are highly related butdiffer by scattered nucleotide substitutions. The antigenic peptideYRPRPRRY, which is also encoded by several other family members, isrecognized by autologous cytolytic T lymphocytes. [provided byRefSeq].

# GAGE2B Antibody (N-term) Blocking Peptide - References

Sun, F., et al. Mol. Cancer Ther. 8(12):3191-3202(2009)Gjerstorff, M.F., et al. Tissue Antigens 71(3):187-192(2008)Ross, M.T., et al. Nature 434(7031):325-337(2005)De Backer, O., et al. Cancer Res. 59(13):3157-3165(1999)Scarcella, D.L., et al. Clin. Cancer Res. 5(2):335-341(1999)